Hydrochlorothiazide And Lisinopril

Introduction Overview

Generic Name

hydrochlorothiazide and lisinopril

Brand Name

Zestoretic

Dosage Form

Oral tablet

Drug Class

ACE inhibitors with thiazides

Pharmacokinetics

Absorption:
Zestoretic combines hydrochlorothiazide (a thiazide diuretic) and lisinopril (an ACE inhibitor). After oral administration, lisinopril is incompletely but rapidly absorbed, with peak plasma concentrations reached approximately 7 hours post-dose. Hydrochlorothiazide is absorbed more rapidly, attaining peak concentrations in 1.5 to 3 hours. Food intake has minimal effect on lisinopril absorption, whereas hydrochlorothiazide absorption may be slightly delayed but not significantly affected. Both components have predictable oral bioavailability supporting once-daily dosing.

Distribution:
Lisinopril exhibits limited protein binding, approximately 25%, facilitating wide tissue distribution but limited penetration into the central nervous system. It primarily distributes in extracellular fluids. Hydrochlorothiazide is around 40% bound to plasma proteins. Distribution volume for lisinopril is approximately 0.1 to 0.2 L/kg, indicating extracellular fluid distribution, while hydrochlorothiazide primarily distributes in plasma and interstitial fluids without significant tissue accumulation. The combination therapy ensures systemic availability of both agents at therapeutic sites.

Metabolism:
Lisinopril is not metabolized by hepatic enzymes and is excreted largely unchanged by the kidneys, indicating negligible hepatic metabolism and low potential for drug interactions via cytochrome P450 pathways. Hydrochlorothiazide also undergoes minimal to no metabolism, relying primarily on renal excretion. This metabolic profile minimizes complex biotransformation but necessitates caution in patients with compromised renal function.

Elimination:
Renal clearance is the principal elimination route for both components. Lisinopril exhibits a plasma half-life of approximately 12 hours, with around 20%-30% excreted unchanged in urine. Hydrochlorothiazide has a half-life ranging between 6 to 15 hours, with about 60%-70% eliminated unchanged in urine. Both drugs require dose adjustment or monitoring in renal impairment to avoid accumulation and adverse effects. Their elimination profiles support once-daily dosing for hypertension management.

Dosage Forms

Available Dosage Forms:
- Oral tablet containing combination doses of hydrochlorothiazide and lisinopril.
Specific available strengths include:
- Hydrochlorothiazide 12.5 mg / Lisinopril 10 mg
- Hydrochlorothiazide 12.5 mg / Lisinopril 20 mg
- Hydrochlorothiazide 25 mg / Lisinopril 10 mg
- Hydrochlorothiazide 25 mg / Lisinopril 20 mg

Dosages for Adults and Adolescents:
- Initial dosing for hypertension typically starts at hydrochlorothiazide 12.5 mg and lisinopril 10 to 20 mg orally once daily.
- Dosage may be titrated every 2 to 3 weeks based on blood pressure response and tolerability.
- Maximum recommended daily doses are hydrochlorothiazide 50 mg and lisinopril 80 mg.
- Dose adjustments may be necessary in patients previously on monotherapy with either component or with electrolyte imbalances, e.g., potassium loss.

Specific Patient Populations:
- Not approved for pediatric use; safety and efficacy have not been established in patients under 18 years.
- Use with caution in patients with renal impairment, as both agents are renally excreted.
- In hepatic impairment or cirrhosis, careful monitoring is advised due to altered volume status and drug metabolism.
- Contraindicated in pregnancy due to risk of fetal toxicity, especially during second and third trimesters.
- Dosage may require modification in elderly patients due to altered renal function and volume status.

Mechanism Of Action

Zestoretic's pharmacodynamic efficacy arises from the complementary actions of its two components: lisinopril and hydrochlorothiazide. Lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, blocks the conversion of angiotensin I to the potent vasoconstrictor angiotensin II. This results in vasodilation, decreased aldosterone secretion, reduced sodium and water retention, and ultimately lowers systemic vascular resistance and blood pressure. By inhibiting ACE, lisinopril also prevents the breakdown of bradykinin, a vasodilatory peptide, which may contribute to its antihypertensive and cardioprotective effects.

Hydrochlorothiazide is a thiazide diuretic that acts primarily on the distal convoluted tubules of the nephron. It inhibits the sodium-chloride symporter, decreasing sodium and chloride reabsorption, which increases excretion of sodium, chloride, and water, reducing plasma volume. This natriuretic effect contributes to decreased preload and overall blood volume, thus lowering blood pressure. Additionally, chronic thiazide therapy reduces peripheral vascular resistance through mechanisms that may involve changes in vascular smooth muscle function.

The combination of lisinopril and hydrochlorothiazide provides synergistic antihypertensive effects: lisinopril’s RAAS inhibition counteracts the potassium loss and volume depletion caused by hydrochlorothiazide, improving electrolyte balance and reducing side effects associated with thiazide monotherapy. This coadministration enhances efficacy and tolerability.

Clinical studies have demonstrated that the fixed-dose combination produces greater reductions in blood pressure and improved patient adherence compared to monotherapy, supporting its use as an effective treatment for hypertension. Furthermore, lisinopril’s cardioprotective effects complement hydrochlorothiazide’s diuretic action in reducing the risks associated with hypertension such as stroke and myocardial infarction.

Pharmacological Actions

Inhibition of angiotensin-converting enzyme leading to decreased angiotensin II and vasodilation
Reduction of aldosterone secretion, decreasing sodium and water retention
Inhibition of sodium-chloride symporter in distal renal tubules to promote diuresis
Lowering plasma volume via increased renal excretion of sodium and water
Decreased systemic vascular resistance resulting in lowered blood pressure
Potassium-sparing effect of lisinopril that counterbalances hydrochlorothiazide-induced potassium loss
Reduction of preload and afterload on the heart through combined diuretic and vasodilatory effects
Improvement of endothelial function by ACE inhibition
Prevention of cardiac and vascular remodeling in hypertension
Modulation of bradykinin levels enhancing vasodilation
Enhanced antihypertensive efficacy through synergistic drug combination
Reduction of proteinuria and nephroprotection in hypertensive patients
Minimal hepatic metabolism leading to lower risk of drug-drug interactions
Improved electrolyte balance compared to thiazide monotherapy
Sustained blood pressure control with once-daily dosing

Therapeutic Or Clinical Uses

Treatment of hypertension (high blood pressure) in adults
Management of fluid retention associated with hypertension
Reduction of risk of stroke and myocardial infarction by blood pressure control
Adjunctive therapy in patients uncontrolled on monotherapy with either ACE inhibitor or thiazide diuretic
Use in patients requiring both diuretic and renin-angiotensin system inhibition
Management of hypertension in patients prone to hypokalemia due to thiazide therapy
Treatment option for patients with coexisting hypertension and mild edema
Improvement of cardiovascular outcomes in hypertensive patients through combination therapy
Use in patients intolerant to higher doses of monotherapy drugs due to side effects
Blood pressure control in patients with high cardiovascular risk factors
Management of hypertension in the elderly with particular attention to electrolyte balance
Reduction of target organ damage secondary to sustained hypertension
Treatment of hypertension in patients with comorbidities such as diabetes (with caution)
Alternative to separate administration of lisinopril and hydrochlorothiazide for better compliance
First-line antihypertensive combination therapy as recommended by clinical guidelines

Side Or Adverse Effects

Persistent dry cough associated with ACE inhibitor component
Dizziness or light-headedness especially upon standing (orthostatic hypotension)
Headache
Fatigue or tiredness
Hyperkalemia symptoms including irregular heartbeats, muscle weakness, or tingling sensations
Hypokalemia-related signs such as muscle cramps, constipation, and cardiac arrhythmias
Hyponatremia symptoms including headache, confusion, and weakness
Gastrointestinal disturbances such as nausea or vomiting
Photosensitivity and increased risk of skin cancer; patients advised to use sun protection
Rare allergic reactions including angioedema with swelling of face, lips, tongue, or throat
Renal impairment or acute kidney injury especially in volume-depleted states
Electrolyte imbalances requiring periodic monitoring
Elevated blood urea nitrogen (BUN) and serum creatinine occasionally observed
Rash or hypersensitivity reactions particularly in sulfa-allergic individuals
Potential for increased blood glucose and uric acid levels
Cough more prevalent in African-American populations
Low blood pressure symptoms such as fainting or weakness

Precautions

Avoid use during pregnancy due to risk of fetal injury or death, especially in second and third trimesters
Monitor serum electrolytes regularly to detect hypo- or hyperkalemia
Use cautiously in patients with renal impairment or on dialysis
Avoid combination with sacubitril-containing medications within 36 hours
Contraindicated in patients with history of angioedema related to ACE inhibitors
Do not use if allergic to sulfa drugs or penicillin without medical consultation
Adjust dose carefully in patients with liver disease or cirrhosis to prevent hypotension
Monitor blood pressure frequently during initiation and dose adjustments
Use with caution in elderly patients due to increased sensitivity to hypotension
Avoid potassium supplements or salt substitutes unless advised by physician
Caution in patients on a low-sodium diet as significant sodium depletion may occur
Avoid dehydration due to risk of renal dysfunction and electrolyte abnormalities
Advise patients to rise slowly from sitting or lying positions to prevent dizziness
Regularly assess for signs of angioedema and discontinue drug immediately if observed
Limit alcohol intake as it can exacerbate blood pressure lowering and side effects
Patients with diabetes should avoid concurrent use with aliskiren-containing medications

Warnings

Pregnancy contraindication due to teratogenicity and fetal toxicity
Increased risk of angioedema, which can be life-threatening requiring immediate medical attention
Potassium imbalance risks including both hyperkalemia and hypokalemia necessitating monitoring
Risk of hypotension especially in volume-depleted or salt-restricted patients
Avoid use within 36 hours of sacubitril to prevent angioedema
Caution with concurrent use of NSAIDs that may impair antihypertensive efficacy and renal function
Risk of renal impairment or acute kidney injury particularly in predisposed individuals
Potential for symptomatic hypotension after initial dose or dose escalation
May cause electrolyte disturbances leading to cardiac arrhythmias
Possible increased risk of skin cancer; patients should avoid excessive sun exposure
Careful monitoring in patients with heart failure or aortic stenosis
Risk of allergic reactions higher in African-American patients
Not approved for pediatric use, safety not established
Discontinue if signs of severe allergic reaction or swelling occur
Do not breastfeed during treatment due to unknown risks to nursing infants

Contraindication

Known hypersensitivity to lisinopril, hydrochlorothiazide, or any components of the formulation
History of angioedema associated with previous ACE inhibitor therapy
Anuria or inability to produce urine
Pregnancy, specifically during the second and third trimesters
Concurrent use with sacubitril within 36 hours
Allergy to sulfonamide-derived drugs, including sulfa drugs
Severe renal impairment without medical supervision
Patients who have experienced angioedema unrelated to ACE inhibitors merit caution or avoidance
Concomitant use with aliskiren in diabetic patients
Known hypersensitivity to other ACE inhibitors or thiazide diuretics
Breastfeeding women due to potential risk to infant
Severe liver impairment where fluid and electrolyte balance is critical
Inadequate renal function as assessed by healthcare provider
Previous severe allergic reactions or anaphylaxis to similar drugs
Known hypersensitivity to penicillin may necessitate caution

Drug Interactions

Concurrent use with sacubitril-containing drugs (e.g., Entresto) increases angioedema risk
NSAIDs (e.g., ibuprofen, naproxen, diclofenac) may reduce antihypertensive effect and impair renal function
Lithium levels may be increased, raising risk of toxicity
mTOR inhibitors such as everolimus, sirolimus, and temsirolimus may increase serum potassium and worsen renal function
Use with potassium supplements or potassium-sparing diuretics can cause hyperkalemia
Aliskiren-containing medications contraindicated in diabetic patients due to risk of adverse renal effects
Other antihypertensive agents may have additive blood pressure lowering effects leading to hypotension
Drugs affecting renal function or electrolyte balance can amplify adverse effects
Concomitant use with other ACE inhibitors or ARBs not recommended due to increased adverse events
Coadministration with diuretics or corticosteroids may alter electrolyte levels requiring monitoring
NSAIDs can blunt natriuretic effect of hydrochlorothiazide leading to reduced efficacy
Use of medications that impair renal function can potentiate risk of hyperkalemia and renal injury
Interactions with antidiabetic drugs may alter glycemic control
Combination with certain immunosuppressants may increase nephrotoxicity risk
Alcohol may potentiate hypotensive effects and increase dizziness

Preparations Of The Drug

Fixed-dose combination oral tablets containing hydrochlorothiazide and lisinopril
Available doses include 12.5 mg hydrochlorothiazide with 10 mg or 20 mg lisinopril
Also available in tablets with 25 mg hydrochlorothiazide combined with 10 mg or 20 mg lisinopril
Supplied for once-daily oral administration
Packaged in bottle or blister packaging for outpatient use
Generic versions are commercially available, enhancing accessibility
Prescribed as part of chronic hypertension management regimens
Not available as injectable or other formulations for this combination
Shelf-stable at room temperature with protection from moisture and excessive heat
Available as branded product Zestoretic and under generic names
Recommended storage away from light and moisture to maintain stability
Tablets are scored for ease of dose adjustment when necessary
No liquid or pediatric formulations currently approved
Prescription-only status requiring healthcare provider oversight
Inner safety packaging often includes medication guides and dosing instructions